{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T02:45:06Z","timestamp":1772678706151,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Bergen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>People with substance use disorders (SUD) have a high prevalence of chronic hepatitis C virus (HCV) infection and mental health disorders. We aimed to assess the impact of integrated HCV treatment on psychological distress measured by Hopkins-symptom-checklist-10 (SCL-10). This multi-center randomized controlled trial evaluated psychological distress as a secondary outcome of integrated HCV treatment (INTRO-HCV trial). From 2017 to 2019, 289 participants were randomly assigned to receive either integrated or standard HCV treatment with direct-acting antiviral therapy. Integrated HCV treatment was delivered in eight decentralized outpatient opioid agonist therapy clinics and two community care centers; standard treatment was delivered in internal medicine outpatient clinics at centralized hospitals. Participants in the integrated treatment arm had a sustained virologic response of 93% compared to 73% for those in standard treatment arm. Psychological distress was assessed using SCL-10 prior to initiation of HCV treatment and 12\u00a0weeks after treatment completion. The mean SCL-10 score prior to HCV treatment was 2.2 (standard deviation [SD]: 0.7) for patients receiving integrated HCV treatment and 2.2 (SD: 0.8) for those receiving standard HCV treatment. Twelve weeks after the end of treatment, the mean SCL-10 score change was \u2212\u20090.1 (\u2212\u20090.3;0.0) in the integrated compared to the standard arm. Psychological distress did not substantially change during the treatment period and was not significantly different between the treatment arms.<\/jats:p>","DOI":"10.1038\/s41598-024-51336-9","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T15:02:29Z","timestamp":1704726149000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of integrated hepatitis C virus treatment on psychological distress in people with substance use disorders"],"prefix":"10.1038","volume":"14","author":[{"given":"Christer F.","family":"Aas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f8rn Henrik","family":"Vold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Chalabianloo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Else-Marie","family":"L\u00f8berg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron G.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Vickerman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kjell Arne","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars Thore","family":"Fadnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"issue":"12","key":"51336_CR1","doi-asserted-by":"publisher","first-page":"e1192","DOI":"10.1016\/S2214-109X(17)30375-3","volume":"5","author":"L Degenhardt","year":"2017","unstructured":"Degenhardt, L. et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: A multistage systematic review. Lancet Global Health 5(12), e1192\u2013e1207 (2017).","journal-title":"Lancet Global Health"},{"issue":"6","key":"51336_CR2","doi-asserted-by":"publisher","first-page":"e1003653","DOI":"10.1371\/journal.pmed.1003653","volume":"18","author":"LT Fadnes","year":"2021","unstructured":"Fadnes, L. T. et al. Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV). PLoS Med. 18(6), e1003653 (2021).","journal-title":"PLoS Med."},{"issue":"1","key":"51336_CR3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13011-021-00354-1","volume":"16","author":"CF Aas","year":"2021","unstructured":"Aas, C. F. et al. Substance use and symptoms of mental health disorders: A prospective cohort of patients with severe substance use disorders in Norway. Subst. Abuse Treat. Prev. Policy 16(1), 20 (2021).","journal-title":"Subst. Abuse Treat. Prev. Policy"},{"issue":"1","key":"51336_CR4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13011-020-00309-y","volume":"15","author":"CF Aas","year":"2020","unstructured":"Aas, C. F. et al. Health-related quality of life of long-term patients receiving opioid agonist therapy: A nested prospective cohort study in Norway. Subst. Abuse Treat. Prev. Policy 15(1), 68 (2020).","journal-title":"Subst. Abuse Treat. Prev. Policy"},{"issue":"1","key":"51336_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13011-020-00334-x","volume":"15","author":"JH Vold","year":"2020","unstructured":"Vold, J. H. et al. Impact of clinical and sociodemographic factors on fatigue among patients with substance use disorder: A cohort study from Norway for the period 2016\u20132020. Subst. Abuse Treat. Prev. Policy 15(1), 93 (2020).","journal-title":"Subst. Abuse Treat. Prev. Policy"},{"issue":"1","key":"51336_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12888-022-03829-y","volume":"22","author":"JH Vold","year":"2022","unstructured":"Vold, J. H. et al. Prevalence and correlates of suicide attempts in high-risk populations: A cross-sectional study among patients receiving opioid agonist therapy in Norway. BMC Psychiatry 22(1), 181 (2022).","journal-title":"BMC Psychiatry"},{"issue":"8","key":"51336_CR7","doi-asserted-by":"publisher","first-page":"e036860","DOI":"10.1136\/bmjopen-2020-036860","volume":"10","author":"JH Vold","year":"2020","unstructured":"Vold, J. H. et al. Potentially addictive drugs dispensing to patients receiving opioid agonist therapy: A register-based prospective cohort study in Norway and Sweden from 2015 to 2017. BMJ Open 10(8), e036860 (2020).","journal-title":"BMJ Open"},{"issue":"1","key":"51336_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13011-020-00286-2","volume":"15","author":"CF Aas","year":"2020","unstructured":"Aas, C. F. et al. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: A drug utilization study from 2014 to 2017. Subst. Abuse Treat. Prev. Policy 15(1), 44 (2020).","journal-title":"Subst. Abuse Treat. Prev. Policy"},{"issue":"1","key":"51336_CR9","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1186\/s12888-023-04980-w","volume":"23","author":"JH Vold","year":"2023","unstructured":"Vold, J. H. et al. Attention-deficit\/hyperactivity disorder (ADHD) symptoms and their relation to diagnosed ADHD, sociodemographic characteristics, and substance use among patients receiving opioid agonist therapy: A Norwegian cohort study. BMC Psychiatry 23(1), 479 (2023).","journal-title":"BMC Psychiatry"},{"issue":"5","key":"51336_CR10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.gastrohep.2022.06.001","volume":"46","author":"L Guti\u00e9rrez-Rojas","year":"2023","unstructured":"Guti\u00e9rrez-Rojas, L. et al. Patients with severe mental illness and hepatitis C virus infection benefit from new pangenotypic direct-acting antivirals: Results of a literature review. Gastroenterol. Hepatol. 46(5), 382\u2013396 (2023).","journal-title":"Gastroenterol. Hepatol."},{"issue":"4","key":"51336_CR11","doi-asserted-by":"publisher","first-page":"e431","DOI":"10.1016\/S2214-109X(20)30505-2","volume":"9","author":"E Oru","year":"2021","unstructured":"Oru, E., Trickey, A., Shirali, R., Kanters, S. & Easterbrook, P. Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: A global systematic review and meta-analysis. Lancet Global Health 9(4), e431\u2013e445 (2021).","journal-title":"Lancet Global Health"},{"key":"51336_CR12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.psychres.2016.06.024","volume":"243","author":"C Roncero","year":"2016","unstructured":"Roncero, C. et al. Psychiatric comorbidities in opioid-dependent patients undergoing a replacement therapy programme in Spain: The PROTEUS study. Psychiatry Res. 243, 174\u2013181 (2016).","journal-title":"Psychiatry Res."},{"issue":"12","key":"51336_CR13","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1080\/09540121.2017.1313384","volume":"29","author":"C Roncero","year":"2017","unstructured":"Roncero, C. et al. HIV And HCV infection among opiate-dependent patients and methadone doses: The PROTEUS study. AIDS Care 29(12), 1551\u20131556 (2017).","journal-title":"AIDS Care"},{"key":"51336_CR14","unstructured":"Hepatitis C among drug users in Europe: Epidemiology, treatment and prevention. European Monitoring Centre for Drugs and Drug Addiction 2016, https:\/\/www.emcdda.europa.eu\/publications\/insights\/hepatitis-c-among-drug-users-in-europe_en (downloaded: 7 Dec 2023)."},{"issue":"1","key":"51336_CR15","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12879-019-3918-2","volume":"19","author":"JH Vold","year":"2019","unstructured":"Vold, J. H. et al. Integrated care of severe infectious diseases to people with substance use disorders; A systematic review. BMC Infect. Dis. 19(1), 306 (2019).","journal-title":"BMC Infect. Dis."},{"issue":"1","key":"51336_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13011-023-00534-1","volume":"18","author":"JH Vold","year":"2023","unstructured":"Vold, J. H. et al. The efficacy of integrated hepatitis C virus treatment in relieving fatigue in people who inject drugs: A randomized controlled trial. Subst. Abuse Treat. Prev. Policy 18(1), 25 (2023).","journal-title":"Subst. Abuse Treat. Prev. Policy"},{"issue":"1","key":"51336_CR17","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1186\/s12879-019-4598-7","volume":"19","author":"LT Fadnes","year":"2019","unstructured":"Fadnes, L. T. et al. Integrated treatment of hepatitis C virus infection among people who inject drugs: Study protocol for a randomised controlled trial (INTRO-HCV). BMC Infect Dis 19(1), 943 (2019).","journal-title":"BMC Infect Dis"},{"issue":"1","key":"51336_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/bs.3830190102","volume":"19","author":"LR Derogatis","year":"1974","unstructured":"Derogatis, L. R., Lipman, R. S., Rickels, K., Uhlenhuth, E. H. & Covi, L. The Hopkins Symptom Checklist (HSCL): A self-report symptom inventory. Behav. Sci. 19(1), 1\u201315 (1974).","journal-title":"Behav. Sci."},{"issue":"2","key":"51336_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1080\/08039480310000932","volume":"57","author":"BH Strand","year":"2003","unstructured":"Strand, B. H., Dalgard, O. S., Tambs, K. & Rognerud, M. Measuring the mental health status of the Norwegian population: A comparison of the instruments SCL-25, SCL-10, SCL-5 and MHI-5 (SF-36). Nordic J. Psychiatry 57(2), 113\u2013118 (2003).","journal-title":"Nordic J. Psychiatry"},{"issue":"6","key":"51336_CR20","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/jgh.12515","volume":"29","author":"JY Wu","year":"2014","unstructured":"Wu, J. Y. et al. Influence of psychiatric diagnosis on treatment uptake and interferon side effects in patients with hepatitis C. J. Gastroenterol. Hepatol. 29(6), 1258\u20131264 (2014).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"1","key":"51336_CR21","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1590\/1516-4446-2018-0336","volume":"42","author":"E Egmond","year":"2020","unstructured":"Egmond, E. et al. Incidence of depression in patients with hepatitis C treated with direct-acting antivirals. Braz. J. Psychiatry 42(1), 72\u201376 (2020).","journal-title":"Braz. J. Psychiatry"},{"issue":"1","key":"51336_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12888-018-1735-6","volume":"18","author":"I Sundberg","year":"2018","unstructured":"Sundberg, I., Lannerg\u00e5rd, A., Ramklint, M. & Cunningham, J. L. Direct-acting antiviral treatment in real world patients with hepatitis C not associated with psychiatric side effects: A prospective observational study. BMC Psychiatry 18(1), 157 (2018).","journal-title":"BMC Psychiatry"},{"key":"51336_CR23","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1471-244X-7-29","volume":"7","author":"K Bakken","year":"2007","unstructured":"Bakken, K., Landheim, A. S. & Vaglum, P. Axis I and II disorders as long-term predictors of mental distress: A 6-year prospective follow-up of substance-dependent patients. BMC Psychiatry 7, 29 (2007).","journal-title":"BMC Psychiatry"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51336-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51336-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51336-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T15:06:11Z","timestamp":1704726371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51336-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51336"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-51336-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,8]]},"assertion":[{"value":"21 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"816"}}